StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Posted by ABMN Staff on Sep 16th, 2024

Investment analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research note issued on Monday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Trading Down 0.0 %

TXMD opened at $1.79 on Monday. The firm’s fifty day moving average is $1.77 and its two-hundred day moving average is $1.97. TherapeuticsMD has a twelve month low of $1.43 and a twelve month high of $3.70.

TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.

Institutional Investors Weigh In On TherapeuticsMD

Several hedge funds have recently bought and sold shares of the company. Clearline Capital LP increased its position in shares of TherapeuticsMD by 18.9% during the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after acquiring an additional 101,282 shares in the last quarter. Prosperity Consulting Group LLC bought a new stake in shares of TherapeuticsMD during the first quarter worth $56,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of TherapeuticsMD during the fourth quarter worth $612,000. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.